Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours (Nature (2017) 543 (65-71) DOI: 10.1038/nature21063);Whole-genome landscape of pancreatic neuroendocrine tumours

Nature

Volumn 543, Issue 7643, 2017, Pages 65-71

  Scarpa, Aldo ^a   Chang, David K ^b,c,d,e,f   Nones, Katia ^g,h   Corbo, Vincenzo ^a   Patch, Ann Marie ^g,h   Bailey, Peter ^b,h   Lawlor, Rita T ^a   Johns, Amber L ^d   Miller, David K ^h   Mafficini, Andrea ^a   Rusev, Borislav ^a   Scardoni, Maria ^a   Antonello, Davide ^a   Barbi, Stefano ^a   Sikora, Katarzyna O ^a   Cingarlini, Sara ^a   Vicentini, Caterina ^a   McKay, Skye ^d   Quinn, Michael C J ^g,h   Bruxner, Timothy J C ^h   Christ, Angelika N ^h   Harliwong, Ivon ^h   Idrisoglu, Senel ^h   McLean, Suzanne ^h   Nourse, Craig ^b,h   Nourbakhsh, Ehsan ^h   Wilson, Peter J ^h   Anderson, Matthew J ^h   Fink, J Lynn ^h   Newell, Felicity ^g,h   Waddell, Nick ^h   Holmes, Oliver ^g,h   Kazakoff, Stephen H ^g,h   Leonard, Conrad ^g,h   Wood, Scott ^g,h   Xu, Qinying ^g,h   Nagaraj, Shivashankar Hiriyur ^h   Amato, Eliana ^a   Dalai, Irene ^a   Bersani, Samantha ^a   Cataldo, Ivana ^a   Dei Tos, Angelo P ⁱ   Capelli, Paola ^a   Davì, Maria Vittoria ^a   Landoni, Luca ^a   Malpaga, Anna ^a   Miotto, Marco ^a   Whitehall, Vicki L J ^g,h,j   Leggett, Barbara A ^g,h,k   Harris, Janelle L ^g   Harris, Jonathan ^l   Jones, Marc D ^b   Humphris, Jeremy ^d   Chantrill, Lorraine A ^d   Chin, Venessa ^d   Nagrial, Adnan M ^d   Pajic, Marina ^d   Scarlett, Christopher J ^d,m   Pinho, Andreia ^d   Rooman, Ilse ^d,ae   Toon, Christopher ^d   Wu, Jianmin ^d,n   Pinese, Mark ^d   Cowley, Mark ^d   Barbour, Andrew ^o   Mawson, Amanda ^d,f   Humphrey, Emily S ^d   Colvin, Emily K ^d   Chou, Angela ^d,p   Lovell, Jessica A ^d   Jamieson, Nigel B ^b,c,q   Duthie, Fraser ^b,r   Gingras, Marie Claude ^s   Fisher, William E ^s   Dagg, Rebecca A ^t   Lau, Loretta M S ^t   Lee, Michael ^u   Pickett, Hilda A ^u   Reddel, Roger R ^u   Samra, Jaswinder S ^u,v   Kench, James G ^d,u,w   Merrett, Neil D ^e,x   Epari, Krishna ^y   Nguyen, Nam Q ^z   Zeps, Nikolajs ^aa,ab,ac   Falconi, Massimo ^a   Simbolo, Michele ^a   Butturini, Giovanni ^a   Van Buren, George ^s   Partelli, Stefano ^a   Fassan, Matteo ^a   Khanna, Kum Kum ^g   Gill, Anthony J ^d,u   Wheeler, David A ^s   Gibbs, Richard A ^s   Musgrove, Elizabeth A ^b   Bassi, Claudio ^a   Tortora, Giampaolo ^a   Pederzoli, Paolo ^a   Pearson, John V ^g,h   Waddell, Nicola ^g,h   Biankin, Andrew V ^b,c,d,e,f   Grimmond, Sean M ^ad   more..

^a UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j Microbiology Division   (Australia)

^k ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^l QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^m UNIVERSITY OF NEWCASTLE   (Australia)

ⁿ PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^o PRINCESS ALEXANDRA HOSPITAL   (Australia)

^p ST VINCENT S HOSPITAL   (Australia)

^q UNIVERSITY OF GLASGOW   (United Kingdom)

^r QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^s BAYLOR COLLEGE OF MEDICINE   (United States)

^t CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^u UNIVERSITY OF SYDNEY   (Australia)

^v ROYAL NORTH SHORE HOSPITAL   (Australia)

^w ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^x UNIVERSITY OF WESTERN SYDNEY   (Australia)

^y FREMANTLE HOSPITAL   (Australia)

^z ROYAL ADELAIDE HOSPITAL   (Australia)

^aa UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^ab ST JOHN OF GOD HOSPITAL   (Australia)

^ac St John of God Subiaco Hospital   (Australia)

^ad UNIVERSITY OF MELBOURNE   (Australia)

^ae VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; CHECKPOINT KINASE 2; DNA GLYCOSYLASE MUTY; DNA GLYCOSYLTRANSFERASE; MAMMALIAN TARGET OF RAPAMYCIN; CALMODULIN BINDING PROTEIN; EWSR1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; RNA BINDING PROTEIN; TARGET OF RAPAMYCIN KINASE;

CYTOGENETICS; DETECTION METHOD; DIGESTIVE SYSTEM; ENZYME; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENOME; INHIBITION; MUTATION; TUMOR;

ARTICLE; CHROMATIN; CHROMOSOME REARRANGEMENT; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; GENE EXPRESSION; GENE FUSION; GERMLINE MUTATION; HUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TELOMERE; TELOMERE HOMEOSTASIS; WHOLE GENOME SEQUENCING; CARCINOMA; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; GENOMICS; HUMAN GENOME; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR;

BASE SEQUENCE; CALMODULIN-BINDING PROTEINS; CARCINOMA, NEUROENDOCRINE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME ABERRATIONS; DNA COPY NUMBER VARIATIONS; DNA GLYCOSYLASES; DNA MUTATIONAL ANALYSIS; DNA REPAIR; FEMALE; GENOME, HUMAN; GENOMICS; GERM-LINE MUTATION; HUMANS; MALE; PANCREATIC NEOPLASMS; RNA-BINDING PROTEINS; TELOMERE; TOR SERINE-THREONINE KINASES;

EID: 85014580625     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature24026     Document Type: Erratum

References (63)

1. Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D. WHO Classification of Tumours of the Digestive System 4th edn (International Agency for Research on Cancer, 2010).
2. Corbo, V. et al. MEN1 in pancreatic endocrine tumors: Analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr. Relat. Cancer 17, 771-783 (2010).
3. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199-1203 (2011).
4. Missiaglia, E. et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 28, 245-255 (2010).
5. Neychev, V. et al. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open 5, e008248 (2015).
6. Elsässer, S. J., Allis, C. D. & Lewis, P. W. Cancer. New epigenetic drivers of cancers. Science 331, 1145-1146 (2011).
7. Heaphy, C. M. et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 333, 425 (2011).
8. Marinoni, I. et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146, 453-460 (2014).
9. Song, S. et al. qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One 7, e45835 (2012).
10. Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5, 5224 (2014).
11. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
12. Popova, T. et al. Genome Alteration Print (GAP): A tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol. 10, R128 (2009).
13. Mermel, C. H. et al. GISTIC2. 0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
14. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
15. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
16. Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47-54 (2016).
17. Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489-494 (2015).
18. Al-Tassan, N. et al. Inherited variants of MYH associated with somatic G:C-< T:A mutations in colorectal tumors. Nat. Genet. 30, 227-232 (2002).
19. Aretz, S. et al. MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p. Tyr179Cys and p. Gly396Asp by founder events. Eur. J. Hum. Genet. 22, 923-929 (2014).
20. Vogt, S. et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137, 1976-1985 (2009).
21. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011).
22. Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59-71 (2012).
23. Georgitsi, M. et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 92, 3321-3325 (2007).
24. Francis, J. M. et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat. Genet. 45, 1483-1486 (2013).
25. Lubensky, I. A. et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am. J. Pathol. 153, 223-231 (1998).
26. Dong, X. et al. Mutations in CHEK2 associated with prostate cancer risk. Am. J. Hum. Genet. 72, 270-280 (2003).
27. Gonzalez-Perez, A. et al. IntOGen-mutations identifies cancer drivers across tumor types. Nat. Methods 10, 1081-1082 (2013).
28. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
29. Li, B. E. et al. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood 122, 2039-2046 (2013).
30. Tang, M. et al. The malignant brain tumor (MBT) domain protein SFMBT1 is an integral histone reader subunit of the LSD1 demethylase complex for chromatin association and epithelial-to-mesenchymal transition. J. Biol. Chem. 288, 27680-27691 (2013).
31. Asai, A. et al. High-resolution 400K oligonucleotide array comparative genomic hybridization analysis of neurofibromatosis type 1-associated cutaneous neurofibromas. Gene 558, 220-226 (2015).
32. Baba, T. et al. Persephin: A potential key component in human oral cancer progression through the RET receptor tyrosine kinase-mitogen-activated protein kinase signaling pathway. Mol. Carcinog. 54, 608-617 (2015).
33. Lindahl, M. et al. Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells. J. Biol. Chem. 276, 9344-9351 (2001).
34. Alers, S., Löffler, A. S., Wesselborg, S. & Stork, B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol. Cell. Biol. 32, 2-11 (2012).
35. Sturm, D. et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164, 1060-1072 (2016).
36. Delattre, O. et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162-165 (1992).
37. May, W. A. et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl Acad. Sci. USA 90, 5752-5756 (1993).
38. Sankar, S. & Lessnick, S. L. Promiscuous partnerships in Ewing's sarcoma. Cancer Genet. 204, 351-365 (2011).
39. Stockman, D. L. et al. Malignant gastrointestinal neuroectodermal tumor: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. Am. J. Surg. Pathol. 36, 857-868 (2012).
40. Brohl, A. S. et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 10, e1004475 (2014).
41. Crompton, B. D. et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 4, 1326-1341 (2014).
42. Tirode, F. et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 4, 1342-1353 (2014).
43. Lovejoy, C. A. et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 8, e1002772 (2012).
44. Sadanandam, A. et al. A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. Cancer Discov. 5, 1296-1313 (2015).
45. Lin, S. Y. & Elledge, S. J. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113, 881-889 (2003).
46. Bar-Peled, L. et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340, 1100-1106 (2013).
47. Fang, M. et al. MEN1 is a melanoma tumor suppressor that preserves genomic integrity by stimulating transcription of genes that promote homologous recombination-directed DNA repair. Mol. Cell. Biol. 33, 2635-2647 (2013).
48. Wang, Y. et al. The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Res. 71, 371-382 (2011).
49. Matkar, S., Thiel, A. & Hua, X. Menin: A scaffold protein that controls gene expression and cell signaling. Trends Biochem. Sci. 38, 394-402 (2013).
50. Landrum M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862-D868 (2016).
51. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
52. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
53. Kambara, T. et al. Role of inherited defects of MYH in the development of sporadic colorectal cancer. Genes Chromosom. Cancer 40, 1-9 (2004).
54. O'Callaghan, N. J. & Fenech, M. A quantitative PCR method for measuring absolute telomere length. Biol. Proced. Online 13, 3 (2011).
55. Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47-52 (2016).
56. Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572-1573 (2010).
57. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
58. Fang, H. & Gough, J. The 'dnet' approach promotes emerging research on cancer patient survival. Genome Med. 6, 64 (2014).
59. Lewis, T. B., Coffin, C. M. & Bernard, P. S. Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissues. Mod. Pathol. 20, 397-404 (2007).
60. Rossi, S. et al. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin. Cancer Res. 13, 7322-7328 (2007).
61. Cai, Z., Chehab, N. H. & Pavletich, N. P. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. Mol. Cell 35, 818-829 (2009).
62. Krieger, E., Koraimann, G. & Vriend, G. Increasing the precision of comparative models with YASARA NOVA-a self-parameterizing force field. Proteins 47, 393-402 (2002).
63. Bell, D. W. et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int. J. Cancer 121, 2661-2667 (2007).